{"id":"NCT04442503","sponsor":"Biogen","briefTitle":"A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)","officialTitle":"A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-08","primaryCompletion":"2022-03-15","completion":"2022-04-12","firstPosted":"2020-06-22","resultsPosted":"2023-06-22","lastUpdate":"2023-11-30"},"enrollment":200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression, Postpartum"],"interventions":[{"type":"DRUG","name":"SAGE-217","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"SAGE-217 50 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.","primaryOutcome":{"measure":"Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15","timeFrame":"Baseline and Day 15","effectByArm":[{"arm":"Placebo","deltaMin":28.8,"sd":2.34},{"arm":"SAGE-217 50 mg","deltaMin":28.6,"sd":2.49}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0007"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":82,"countries":["United States","Spain","United Kingdom"]},"refs":{"pmids":["37491938"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":98},"commonTop":["Somnolence","Dizziness","Headache","Sedation","Nausea"]}}